Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Cancer Discovery (2023) Vol. 13, Iss. 9, pp. 2012-2031
Open Access | Times Cited: 65

Showing 26-50 of 65 citing articles:

S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 03, pp. e159-e260
Closed Access
Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations
Yasuaki Uemoto, Chang-Ching Lin, Bingnan Wang, et al.
Cancer Letters (2025), pp. 217668-217668
Closed Access
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
Turçin Saridogan, Argun Akçakanat, Ming Zhao, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine
Takafumi Mie, Takashi Sasaki, Takeshi Okamoto, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 879-879
Open Access | Times Cited: 3
Are FGFR Fusions and Mutations the Next Tumor-Agnostic Targets in Oncology?
Haley Ellis, Lipika Goyal
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 3
Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer
Mei Peng, Jun Deng, Xiangping Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 3
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling
Lipika Goyal, Daniel DiToro, Antoine Hollebecque, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 3
Biomolecular simulations at the exascale: From drug design to organelles and beyond
Vytautas Gapsys, Wojciech Kopeć, Dirk Matthes, et al.
Current Opinion in Structural Biology (2024) Vol. 88, pp. 102887-102887
Open Access | Times Cited: 2
Targeting FGFR Pathways in Gastrointestinal Cancers: New Frontiers of Treatment
Margherita Ratti, Elena Orlandi, Jens C. Hahne, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2650-2650
Open Access | Times Cited: 6
Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
Ángela Lamarca, Arndt Vogel
ESMO Open (2023) Vol. 8, Iss. 6, pp. 102049-102049
Open Access | Times Cited: 5
B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling
Amulya Sreekumar, Michelle Lu, Biswa Choudhury, et al.
Cancer Cell (2023) Vol. 42, Iss. 1, pp. 52-69.e7
Open Access | Times Cited: 5
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations
Eranga R. Balasooriya, Qibiao Wu, Haley Ellis, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2181-2192
Closed Access | Times Cited: 1
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma
Philipp Heumann, Andreas Albert, Karsten Gülow, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1690-1690
Open Access | Times Cited: 1
Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor
Huiqiong Li, Ke Ran, Yang Zhou, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116473-116473
Closed Access | Times Cited: 1
Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors
Wuqing Deng, Xiaojuan Chen, Hong Liang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116558-116558
Closed Access | Times Cited: 1
Integrating Molecular Insights into Biliary Tract Cancer Management: A Review of Personalized Therapeutic Strategies
Mar Ros-Buxó, Ezequiel Mauro, Tamara Saurí, et al.
Current Oncology (2024) Vol. 31, Iss. 7, pp. 3615-3629
Open Access | Times Cited: 1
Overcoming treatment resistance in cholangiocarcinoma: current strategies, challenges, and prospects
Jiayi Wang, Siyan Liu, Yi Cao, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 1
Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer
Ahmed Elhariri, Jaydeepbhai Patel, Himil Mahadevia, et al.
Targeted Oncology (2024) Vol. 19, Iss. 5, pp. 679-689
Closed Access | Times Cited: 1
Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1
Xingkang Wu, Yang Li, Chenchen Han, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9226-9226
Open Access | Times Cited: 1
Pharmacological and Biological Targeting of FGFR1 in Cancer
Shuai Fan, Yuxin Chen, Wenyu Wang, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 11, pp. 13131-13150
Open Access | Times Cited: 1
Specific Inhibition of Fibroblast Growth Factor Receptor 1 Signaling by a DNA aptamer
Vladimira Zlinska, Zuzana Feketová, Aleksandra Czyrek, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 36, Iss. 1, pp. 102405-102405
Open Access | Times Cited: 1
Fibroblast growth factor therapies in biliary tract cancers: current and future state
Teerada Siripoon, Conor O’Donnell, Zhaohui Jin, et al.
Expert Opinion on Investigational Drugs (2024), pp. 1-11
Closed Access | Times Cited: 1
Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance
Haley Ellis, Chiara Braconi, Juan W. Valle, et al.
American Journal Of Pathology (2024)
Closed Access | Times Cited: 1
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications
Elisabeth Amadeo, Federico Rossari, Francesco Vitiello, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 7, pp. 631-642
Closed Access | Times Cited: 3
FGFR Inhibition: Understanding and Overcoming Resistance
Abhishek Tripathi, Daneng Li, Sumanta K. Pal
Cancer Discovery (2023) Vol. 13, Iss. 9, pp. 1964-1965
Closed Access | Times Cited: 3

Scroll to top